Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.98 |
| ▸ | LMNA | P02545 | 4/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.50 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8291363 | 0.99 | MAPT (1.00) | MAPTLMNACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8291314 | 0.88 | MAPT (0.80) | MAPTLMNACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8290632 | 0.86 | MAPT (0.77) | MAPTLMNACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL29387235 | 0.83 | MAPT (0.72) | MAPTLMNACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8290637 | 0.82 | MAPT (0.73) | MAPTLMNACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8290633 | 0.82 | MAPT (1.00) | MAPTLMNACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8289597 | 0.79 | MAPT (1.00) | MAPTLMNACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL12266674 | 0.78 | MAPT (0.64) | MAPTLMNACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8305070 | 0.77 | KCNA5 (0.76) | MAPTLMNACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL10727154 | 0.77 | MAPT (0.63) | MAPTLMNACYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263636-B2 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | IMTM GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8263636-B2 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | IMTM GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| EP-2105441-A1 | Alanyl aminopeptidase and dipeptidylpeptidase IV dual inhibitors for the treatment of immunological, inflammatory, neuronal and other illnesses | IMTM GmbH (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-04-05 | — | — | US | disclosed |
| WO-2005034940-A2 | DUAL ALANYL AMINOPEPTIDASE AND DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND FOR TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | DNPEP, PREP, ANPEP | MAPT 1296/4885LMNA 3650/4885CYP3A4 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.